NCT03438318View on ClinicalTrials.gov

Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

December 11, 2019

Study Completion Date

December 11, 2019

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

CMP-001

CMP-001 will be administered as per the dose and schedule specified in the respective arms.

DRUG

Atezolizumab

Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.

RADIATION

Radiation Therapy

Radiation therapy will be administered using either 3-dimensional (3D) conformal radiotherapy or intensity-modulated radiation therapy (IMRT) to non-target node or metastatic lesion as per the dose and schedule specified in the respective arms.

Trial Locations (5)

52242

University of Iowa Hospitals and Clinics, Iowa City

77030

MD Anderson, Houston

80045

University of Colorado Aurora, Aurora

85234

Banner MD Anderson Cancer Center, Gilbert

91010

City of Hope Medical Center, Duarte

Sponsors

Collaborators (1)

Novella Clinical
All Listed Sponsors
collaborator

Novella Clinical

OTHER

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT03438318 - Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter